Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada

被引：2

作者：

Jiang, Di Maria ^{[1
]}

North, Scott A. ^{[2
]}

Canil, Christina ^{[3
]}

Kolinsky, Michael ^{[2
]}

Wood, Lori A. ^{[4
]}

Gray, Samantha ^{[5
]}

Eigl, Bernhard J. ^{[6
]}

Basappa, Naveen S. ^{[2
]}

Blais, Normand ^{[7
,8
]}

Winquist, Eric ^{[9
]}

Mukherjee, Som D. ^{[10
]}

Booth, Christopher M. ^{[11
]}

Alimohamed, Nimira S. ^{[12
]}

Czaykowski, Piotr ^{[13
]}

Kulkarni, Girish S. ^{[14
,15
]}

Black, Peter C. ^{[16
]}

Chung, Peter W. ^{[17
]}

Kassouf, Wassim ^{[18
]}

van der Kwast, Theodorus ^{[19
]}

Sridhar, Srikala S. ^{[1
]}

机构：

[1] Univ Toronto, Dept Med, Div Med Oncol & Hematol, Univ Hlth Network,Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Univ Alberta, Cross Canc Inst, Div Med Oncol, Dept Oncol, Edmonton, AB, Canada

[3] Univ Ottawa, Ottawa Hosp Canc Ctr, Div Med Oncol, Dept Internal Med, Ottawa, ON, Canada

[4] Dalhousie Univ, Div Med Oncol, Queen Elizabeth II Hlth Sci Ctr, Dept Med, Halifax, NS, Canada

[5] Dalhousie Univ, Dept Oncol, St John Reg Hosp, Dept Med, St John, NB, Canada

[6] Univ British Columbia, Dept Med, Div Med Oncol, BC Canc Vancouver, Vancouver, BC, Canada

[7] Ctr Hosp Univ Montreal, Dept Med, Div Med Oncol & Hematol, Montreal, PQ, Canada

[8] Univ Montreal, Montreal, PQ, Canada

[9] Univ Western Ontario, Dept Oncol, London Hlth Sci Ctr, London, ON, Canada

[10] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada

[11] Queens Univ, Dept Oncol, Kingston, ON, Canada

[12] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada

[13] Univ Manitoba, Dept Med Oncol & Hematol, Canc Care Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada

[14] Univ Toronto, Dept Surg, Div Urol, Princess Margaret Canc Ctr,Univ Hlth Network, Toronto, ON, Canada

[15] Univ Toronto, Dept Surg Oncol, Div Urol, Princess Margaret Canc Ctr,Univ Hlth Network, Toronto, ON, Canada

[16] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada

[17] Univ Toronto, Dept Radiat Oncol, Radiat Med Program, Princess Margaret Canc Ctr,Univ Hlth Network, Toronto, ON, Canada

[18] McGill Univ, Dept Urol, Ctr Hlth, Montreal, PQ, Canada

[19] Univ Hosp Network, Lab Med Program, Toronto, ON, Canada

来源：

BLADDER CANCER | 2020年 / 6卷 / 03期

关键词：

Urinary bladder neoplasms; consensus; diagnosis; follow-up; treatment; neoadjuvant therapy; adjuvant therapy; TRANSITIONAL-CELL-CARCINOMA; LONG-TERM OUTCOMES; CISPLATIN-BASED CHEMOTHERAPY; GEMCITABINE PLUS CISPLATIN; SELECTIVE ORGAN PRESERVATION; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; RECEIVING NEOADJUVANT CHEMOTHERAPY; METASTATIC UROTHELIAL CARCINOMA; COMBINED-MODALITY TREATMENT; GLOMERULAR-FILTRATION-RATE;

D O I：

10.3233/BLC-200291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Despite recent advances in the management of muscle-invasive bladder cancer (MIBC), treatment outcomes remain suboptimal, and variability exists across current practice patterns. OBJECTIVE: To promote standardization of care for MIBC in Canada by developing a consensus guidelines using a multidisciplinary, evidence-based, patient-centered approach who specialize in bladder cancer. METHODS: A comprehensive literature search of PubMed, Medline, and Embase was performed; and most recent guidelines from national and international organizations were reviewed. Recommendations were made based on best available evidence, and strength of recommendations were graded based on quality of the evidence. RESULTS: Overall, 17 recommendations were made covering a broad range of topics including pathology review, staging investigations, systemic therapy, local definitive therapy and surveillance. Of these, 10 (59%) were level 1 or 2, 7 (41%) were level 3 or 4 recommendations. There were 2 recommendations which did not reach full consensus, and were based on majority opinion. This guideline also provides guidance for the management of cisplatin-ineligible patients, variant histologies, and bladder-sparing trimodality therapy. Potential biomarkers, ongoing clinical trials, and future directions are highlighted. CONCLUSIONS: This guideline embodies the collaborative expertise from all disciplines involved, and provides guidance to further optimize and standardize the management of MIBC.

引用

页码：363 / 392

页数：30

共 306 条

[1] The Sensitivity of Initial Transurethral Resection or Biopsy of Bladder Tumor(s) for Detecting Bladder Cancer Variants on Radical Cystectomy [J].